Navigation Links
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2011 and Provides Update on Development Activities
Date:8/4/2011

d the investigator-sponsored Phase 1 trial evaluating OGX-427 in patients with superficial bladder cancer. We expect results from both trials in 2012, unchanged from previous guidance.
  • We expect to initiate the randomized Phase 2 clinical trial of OGX-427 in approximately 180 patients with metastatic bladder cancer in the second half of 2011.

  • Financial Results

  • Revenue for the second quarter increased to $1.9 million compared with $1.7 million in 2010. Revenue for the six months ended June 30, 2011 decreased to $3.1 million from $6.4 million in 2010. Revenue is earned through reimbursements received under the Teva collaboration, as well as recognition of upfront payments we received from Teva.  
  • Revenue increased for the second quarter of 2011 due to increased efforts associated with the custirsen Phase 3 clinical trials.
  • Revenue decreased during the six months ended June 30, 2011 due to custirsen manufacturing activities now being paid directly by Teva.
  • As of June 30, 2011, $19.9 million of the $30.0 million upfront payment received from Teva in December 2009 was included in our Balance Sheet as Deferred Collaboration Revenue, which we are recognizing as we perform our deliverables under the agreement. We currently expect this performance period to end in the fourth quarter of 2013.
  • Total operating expenses for the second quarter increased to $6.9 million from $4.6 million in the second quarter of 2010.  Total operating expenses for the six months ended June 30, 2011 also increased to $13.3 million from $12.3 million during the same period in 2010.
  • The increase in operating expenses was primarily due to higher manufacturing and clinical trial costs for OGX-427, and higher employee expenses, offset by lower custirsen manufacturing costs that are now being paid directly by Teva.
  • Net loss for the second quarter of 2011 increased to $6.5 million, or $0.67 per diluted com
    '/>"/>

  • SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. OncoGenex Announces Data Highlighting OGX-427 at American Association of Cancer Research (AACR) 102nd Annual Meeting 2011
    2. OncoGenex Pharmaceuticals to Participate in Panel Discussion on Novel Cancer Treatments at RBC Capital Markets Healthcare Conference
    3. Isis Pharmaceuticals to Receive $10 Million From OncoGenex License of OGX-011 to Teva
    4. OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer
    5. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2011 Financial Results
    6. Pacira Pharmaceuticals, Inc. Announces Data Presentations at the 38th Annual Meeting & Exposition of the Controlled Release Society
    7. Pacira Pharmaceuticals, Inc. Announces Timing for Second Quarter 2011 Financial Results Webcast and Conference Call
    8. Visionary Pharmaceuticals, Inc., Announces Initial Seed Round Investments and the Launch of TH17 Autoimmune Disease Research Activities
    9. Janssen Pharmaceuticals, Inc. Announces Definitive Agreement to Divest Ortho Dermatologics Division
    10. Gamma Pharmaceuticals, Inc. Holds Special Shareholders Meeting
    11. Sigma-Tau Pharmaceuticals, Inc. Announces Addition of VP of Finance
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2015)... 2015  Semler Scientific, Inc. (Nasdaq: SMLR ), ... healthcare insurers and physician groups, today reported financial results ... "In the second quarter of 2015, Semler ... of 54%, quarter over quarter revenue growth of 8%, ... of FloChec® units of 18%," said Doug Murphy-Chutorian, M.D., ...
    (Date:7/31/2015)... SAN DIEGO , July 31, 2015  Eisai ... Ltd. (Headquarters: Tokyo , President and ... Inc. (Headquarters: San Diego, California , ... HALO") have signed a clinical collaboration agreement to evaluate ... in combination with Halozyme,s investigational drug PEGPH20 (PEGylated recombinant ...
    (Date:7/31/2015)... , July 31, 2015  Xencor, Inc. (NASDAQ: ... antibodies for the treatment of autoimmune diseases, asthma and ... Yujiro S. Hata to its board of ... business and corporate development is a tremendous asset to ... and chief executive officer of Xencor. "Xencor faces a ...
    Breaking Medicine Technology:Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
    ... - the novel,selective relaxant binding agent (SRBA) being ... Akzo Nobel - demonstrated in,a Phase III pivotal ... as compared to neostigmine, without evidence,of post operative ... The results of this pivotal Aurora trial,were presented ...
    ... 11, 2007 (MARKET WIRE via COMTEX News,Network) ... target=,"_blank" href="http://www.myriad.com/">www.myriad.com ),announced today that it presented ... a "Randomized Withdrawal" clinical trial,design with a ... the Alzheimer's Association Prevention Conference held,June 9 ...
    Cached Medicine Technology:Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in,Phase III Pivotal Trial Compared to Neostigmine 2Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in,Phase III Pivotal Trial Compared to Neostigmine 3Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 2Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 3Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 4Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 5
    (Date:7/31/2015)... , ... July 31, 2015 , ... ... announced plans to release a newly redesigned website at Healthpointe.net. The new website ... user experience. , The redesign serves to provide smoother interactions between patients ...
    (Date:7/31/2015)... ... July 31, 2015 , ... The Women's ... Center for Natural Birth . The Karmanos Center for Natural Birth provides ... experience. With nurses and caregivers that are trained in holistic birth approaches, patients ...
    (Date:7/31/2015)... ... July 31, 2015 , ... A ... natural, therapeutic-grade oils from ingredients sourced all over the world, then manufactured into ... effort, we have developed the highest-quality oils in the industry, which we are ...
    (Date:7/31/2015)... ... July 31, 2015 , ... Super-Sod wants to participate in planning new home ... as the perfect fit for such a goal. Houzz is a social media ... is a dynamic site that spreads home and home garden design ideas when members ...
    (Date:7/31/2015)... Orlando, FL (PRWEB) , ... July 31, 2015 , ... ... visiting the United States for temporary work, study or family visit for the past ... in their 80s and 90s are able to travel and spend time with their ...
    Breaking Medicine News(10 mins):Health News:Healthpointe Announces Newly Redesigned Website 2Health News:Living Pure Essential Oils takes Therepeutic Essential Oil Market by Storm 2Health News:Super-Sod Created a Landscape Profile on Houzz.com for Home Garden Design 2Health News:India Network Visitor Health Insurance Announces Completion of Food Grains Distribution to Godavari Pushkaram Visitors, Andhra Pradesh, India 2Health News:India Network Visitor Health Insurance Announces Completion of Food Grains Distribution to Godavari Pushkaram Visitors, Andhra Pradesh, India 3
    ... growing brain tumors must adjust to periods of low ... cells grow and proliferate. When levels are low, the ... Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer ... the switch responsible for this grow-or-go behavior. , Their ...
    ... that the company received Registration Certificate for its MEVAC-Vari vaccine in Guatemala . , ... , , ... ... ...
    ... author, and lecturer Dr. William Sears and his product team have announced the launch of ... Expo West convention to be held in Anaheim, CA March 12-14 . The company,s ... ... ...
    ... ... and food security has wide-ranging benefits compared to its costs in the fight against ... Congressional hearing on global hunger. He cites findings from Nobel laureates and a Lancet ... ...
    ... ... ... 11, 2010 -- Qualifacts Systems Inc. , the largest Software as a Service ... and human services providers, has added New Directions Inc. to its client roster – ...
    ... ... President of International Orion Health – Charles Scatchard. Orion Health celebrates “phenomenal success” with ... , ... (PRWEB) March 12, 2010 -- To further the ongoing success with implementing Healthcare IT ...
    Cached Medicine News:Health News:Researchers discover brain tumor's 'grow-or-go' switch 2Health News:Researchers discover brain tumor's 'grow-or-go' switch 3Health News:Hard to Treat Diseases (HTDS) Acquired Varicella Approval in Guatemala 2Health News:Hard to Treat Diseases (HTDS) Acquired Varicella Approval in Guatemala 3Health News:Hard to Treat Diseases (HTDS) Acquired Varicella Approval in Guatemala 4Health News:Hard to Treat Diseases (HTDS) Acquired Varicella Approval in Guatemala 5Health News:America's Pediatrician Dr. Bill Sears Answers Michelle Obama's Call to Action to Help Eradicate Obesity 2Health News:America's Pediatrician Dr. Bill Sears Answers Michelle Obama's Call to Action to Help Eradicate Obesity 3Health News:Nutritional Aid is Cost-effective Measure Against Health and Hunger Problems, World Vision Tells Congress 2Health News:Nutritional Aid is Cost-effective Measure Against Health and Hunger Problems, World Vision Tells Congress 3Health News:Qualifacts is Behavioral Health SaaS Provider of Choice in Connecticut 2Health News:Orion Health Showcases Industry Leading EHR Software at WoHIT 2Health News:Orion Health Showcases Industry Leading EHR Software at WoHIT 3Health News:Orion Health Showcases Industry Leading EHR Software at WoHIT 4Health News:Orion Health Showcases Industry Leading EHR Software at WoHIT 5
    PremierEdge™ Stab Knives - 45°....
    PremierEdge Stab Knives - 15....
    More Info Lacrimal Intubation Set. Size: Probes 23g x 7"....
    ... use of the Leica CM1900 as well ... the instrument of choice in many routine ... open top stainless steel cryochamber with separate ... ample space for convenient working and storage ...
    Medicine Products: